VenaCure-EVLT.com offers practice development tools, helps patients find physicians
Queensbury, N.Y. (PRWEB) November 5, 2009 -- AngioDynamics (NASDAQ: ANGO) launched a new Web site at the American College of Phlebology's 23rd Annual Congress giving physicians access to practice development tools and updates on the treatment of venous disease. It also features content targeted to patients, including a physician locator for patients seeking doctors who use the VenaCure EVLT™ system, and provides email, phone and website referrals to AngioDynamics' customers.
Key features of VenaCure-EVLT.com unveiled at the Congress - held in Palm Desert, California, November 5-8 - include a section for physicians that augments what is already the industry's most comprehensive vein practice development program. In addition to information on its entire endovenous laser therapy product line, VenaCure-EVLT.com provides marketing support tools, reimbursement information, a link to a fully accredited Continuing Medical Education course, thorough clinical and technical information and a dedicated AngioDynamics contact for personalized customer care.
"AngioDynamics' new VenaCure-EVLT.com site is another way in which we continue to build our place as the leader in laser vein ablation, creating a destination where physicians can get valuable support for their practice and up-to-date information on what we know about varicose veins, spider veins and appropriate treatments," said Shawn McCarthy, Senior Vice President and General Manager of the Company's Peripheral Vascular Business Unit. "VenaCure-EVLT.com will also be a valuable tool for patients, giving them access to useful and fresh information, and making it easier for them to understand the underlying disease. We believe physicians working with us will see an increase in patients who are looking for the right solution."
VenaCure-EVLT.com gives patients an understanding of the progressive disease underlying varicose veins, relevant clinical findings, updates on insurance coverage and an electronic newsletter that regularly keeps subscribers apprised of advancements in varicose vein laser ablation.
AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "potential," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to execute its leadership development plan and integrate purchased businesses, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Read the full story at http://www.prweb.com/releases/2009/11/prweb3162974.htm.
Copyright©2009 Vocus, Inc.
All rights reserved